Peptide education
Vancomycin
Vancomycin hydrochloride · Vancocin
Vancomycin is a glycopeptide antibiotic. Intravenous treatment addresses certain serious bacterial infections throughout the body; oral treatment is used for specific infections in the intestine.
The infection, organism, and route determine how vancomycin is used. The oral capsule label covers C. difficile-associated diarrhea and staphylococcal enterocolitis. The injection label covers specified serious infections and also describes preparing its formulation for oral use in specified intestinal infections.
Overview
Quick answer
Oral vancomycin is not effective for the systemic infections treated with intravenous therapy. Intravenous treatment alone is not effective for the intestinal infections listed on the capsule label.
What does oral vancomycin treat?
Vancocin capsules are labeled for C. difficile-associated diarrhea and enterocolitis caused by Staphylococcus aureus, including resistant strains.
Can oral capsules replace IV treatment for a bloodstream infection?
No. The oral label says capsules are not effective for other types of infections. The injection and capsule labels describe different uses.
Is oral vancomycin never absorbed?
No. Although oral treatment acts in the intestine, clinically significant blood concentrations can occur in some patients, including people with intestinal inflammation or kidney impairment.
Can an injection product be prepared for oral use?
The cited injection label describes preparing its parenteral formulation for oral administration for specified intestinal infections. Giving the medicine by mouth is different from giving it intravenously.
Why does the IV infusion rate matter?
The injection label links infusion reactions to concentration and rate. It specifies no more than 10 mg per minute or at least 60 minutes, whichever is longer, while noting reactions can still occur.
Evidence
Evidence snapshot
Clinical cures in the oral vancomycin group of the modified intention-to-treat analysis; fidaxomicin was the comparator.
Vancomycin was one option combined with initial gentamicin, not the entire comparator.
Recurrence with vancomycin versus fidaxomicin among initially cured participants in the registry's separate analysis, with 222 per group. The publication and registry report different modified analysis group counts.
Clinically significant blood concentrations have occurred in some patients.
Monitoring and infusion rate are addressed in the injection label.
Claims
Common claims vs evidence
| Claim | Human evidence | Verdict |
|---|---|---|
| Oral and intravenous vancomycin can be swapped without changing the treatment. | The capsule label covers intestinal infections and says oral treatment is not effective for other infections. It also says parenteral treatment is not effective for the intestinal conditions named there. | The routes have distinct therapeutic roles. |
| Oral vancomycin can never cause systemic adverse effects. | The capsule label reports clinically significant blood concentrations in some patients and describes nephrotoxicity after oral treatment. | Systemic absorption can occur, particularly in some higher-risk settings. |
| The bacteremia trial compared daptomycin against vancomycin alone. | Standard therapy included initial low-dose gentamicin plus either vancomycin or an antistaphylococcal penicillin. | The reported comparator outcome is pooled across the standard-therapy strategy. |
| Similar initial cure means the treatments had the same recurrence rate. | The publication reported similar initial cure in the modified analysis. Among initially cured participants, the registry reported recurrence in 27.0% with vancomycin and 12.6% with fidaxomicin. | Initial cure and recurrence are separate outcomes. |
Bottom line
Main takeaway
Oral capsules and IV vancomycin treat different types of infection.
Kidney function, other medicines, and the IV infusion rate are important considerations.
C. difficile clinical cure is an intestinal outcome; the bacteremia comparator was a combination strategy.
Identity
What it is
Vancomycin acts against susceptible Gram-positive organisms by interfering with cell-wall construction. Resistance and infection site matter.
The injection label includes serious infections caused by susceptible methicillin-resistant staphylococci. Vancocin capsules have separate intestinal indications.
The cited injection label also describes preparing its parenteral formulation for oral administration for specified intestinal infections. The route given, not only the product name, matters.
Use context
Routes, doses, and cycle patterns
The cited U.S. labels describe separate oral and intravenous dosing contexts.
Human studies and product labels
Adult C. difficile-associated diarrhea
- Purpose
- Intestinal infection
- Context
- Vancocin capsule label
- Route
- Oral
- Amount
- 125 mg
- Frequency
- Four times daily
- Duration
- 10 days
The same capsule label gives a different total daily dose and duration for staphylococcal enterocolitis.
Adult intravenous label example
- Purpose
- Serious susceptible systemic infection
- Context
- Injection label, normal renal function
- Route
- Intravenous infusion
- Amount
- 1 g every 12 hours or 500 mg every 6 hours
- Frequency
- Divided throughout the day
The label specifies no faster than 10 mg per minute or at least 60 minutes, whichever is longer. Age, obesity, kidney function, and serum concentrations can affect dosing decisions.
C. difficile trial
- Purpose
- Acute toxin-positive C. difficile infection
- Context
- Study-reported randomized regimen
- Route
- Oral
- Amount
- 125 mg
- Frequency
- Every 6 hours
- Duration
- 10 days
The comparator was fidaxomicin; the primary endpoint was clinical cure.
What varies
- Route: oral treatment targets labeled intestinal infections; IV treatment targets systemic infections.
- Kidney function: exposure and risk can change with renal impairment.
Research
Research evidence
A randomized intestinal-infection trial compared oral vancomycin with fidaxomicin. A separate bacteremia trial included IV vancomycin as one component of a pooled standard-therapy strategy.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| C. difficile infection | Patients aged 16 or older with acute toxin-positive C. difficile infection | Randomized, double-blind noninferiority trial | Oral vancomycin versus oral fidaxomicin | The publication reported clinical cure in 223 of 257 and 221 of 252 patients, respectively. The registry reported recurrence in 27.0% and 12.6% of initially cured participants, respectively. | Initial cure and recurrence are different endpoints. The publication and registry report different modified analysis group counts. | Strong |
| S. aureus bacteremia and endocarditis | Patients with S. aureus bacteremia, with or without endocarditis | Randomized active-comparator trial | Daptomycin versus gentamicin plus either vancomycin or penicillin | Success occurred in 53 of 120 versus 48 of 115 patients in the modified analysis. | The comparator success rate is pooled, not a vancomycin-only result. | Strong |
Cautions
Safety and unknowns
- The injection label warns of nephrotoxicity and ototoxicity and discusses monitoring serum levels and kidney function.
- Infusion-related reactions can occur even when the recommended rate and concentration limits are followed.
- Oral capsules can produce clinically significant blood concentrations in some patients; the label reports kidney toxicity after oral treatment.
- Both labels warn of serious skin reactions and hypersensitivity.
Product quality
Product identity and quality
Prescription capsules and the cited injection product have different labeling and preparation instructions; the administration route matters.
The cited injection label also describes preparing that formulation for oral use in specified intestinal infections.
Product and route
Oral and parenteral therapy are not interchangeable for the infections named on the capsule label.
Mechanism
How it is proposed to work
Vancomycin blocks a step bacteria need to build their protective cell wall.
It binds the D-alanyl-D-alanine end of cell-wall precursors, interfering with peptidoglycan synthesis.
FAQ
Common questions
Can oral vancomycin replace IV treatment for bloodstream infection?
No. The oral capsule label says it is not effective for other types of infections beyond the specified intestinal uses.
Can an injection product be prepared for oral use?
The cited injection label describes preparing its parenteral formulation for oral administration for specified intestinal infections. That is different from administering it intravenously.
Can oral vancomycin be absorbed?
Yes. Clinically significant concentrations have been reported in some patients, including people with active C. difficile diarrhea or inflamed intestinal mucosa.
Details
Technical details
Sources
References
- 1.
- 2.
- 3.
PubMed. Daptomycin versus standard therapy for Staphylococcus aureus bacteremia and endocarditis
doi:10.1056/NEJMoa053783 PMID:16914701 NCT00093067
- 4.
PubMed. Randomized comparison of fidaxomicin and vancomycin for C. difficile infection
doi:10.1016/S1473-3099(11)70374-7 PMID:22321770 NCT00468728
- 5.
ClinicalTrials.gov. Fidaxomicin and vancomycin trial results
NCT00468728
The registry and publication report different modified analysis group counts.
- 6.
PubMed. Vancomycin binding to bacterial cell-wall peptide analogues
doi:10.7164/antibiotics.48.805 PMID:7592024